Radiation for Lung Cancer: 264 Real Stories

264 stories match lung cancer and radiation. 187 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 ALK-positive lung cancer: remission on lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: ALK-positive rearrangement; TTF-1-positive

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bone, liver,…

Metastatic ALK-positive lung adenocarcinoma remained in radiologic and clinical remission on lorlatinib after CNS progression on earlier ALK-directed therapy and stereotactic radiosurgery.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small-cell lung cancer: ongoing response to immunotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-negative

Metastatic Site: liver, bone, brain

Extensive-stage small-cell lung cancer had complete response in the primary lung, liver, bone, and treated brain lesions, with partial response in hilar/mediastinal nodes; after about 20 months of serplulimab-based first-line therapy, the patient had no deterioration, no immunotherapy-related adverse effects, and high quality of life.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage II Lung AdenocarcinomaLung Cancer

Recurrent Lung Adenocarcinoma Complicated by a Tracheopericardial Fistula

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: No gene mutations identified on postoperative testing

He died during the June 2024 admission, about 7½ years after his November 2016 lung-cancer diagnosis, after massive hemoptysis occurred in the setting of a tracheopericardial fistula and recurrent cancer.

PubMed Central
OutcomeIn Memory
Ashley, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley Vasallo, Female, Under 40 | Stage IV

Biomarkers: No actionable driver biomarker identified; rare fusion reported

Metastatic Site: spine, hip/bone, chest cavity

As of October 2024, Ashley reported clear labs and scans after radiation for small chest-cavity and hip lesions, with scans planned every 3 months.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Metastatic Lung Cancer With Morphine-Induced Fever During Palliative Radiation

Patient Info: Anonymized, female, 50s | Stage IV

Metastatic Site: brain, bone

She remained on dacomitinib while receiving radiation for painful metastatic disease in 2022. After morphine was identified as the cause of recurrent fever and stopped, her symptoms resolved and she was discharged in satisfactory condition.

PubMed Central
OutcomeCare Ongoing
Pascal, who was diagnosed with Lung CancerLung Cancer

Lung Cancer: Pascal's Survivor Story

Patient Info: Pascal, Male, 60s

As of the September 2024 article update, Pascal had resumed sports, felt well, and had been in complete remission for 26 months after an immunotherapy clinical trial following chemotherapy and radiation failure.

CancerConsult (FR)
OutcomeCancer-Free / NED
Florence, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Florence's Patient Story

Patient Info: Florence, Female, 40s | Stage IV

Metastatic Site: Brain

As of the September 2024 article update, Florence was living with metastatic lung cancer, traveling every 3 weeks for immunotherapy in a clinical trial, and reported less fatigue, more energy, and a return to sports and social life.

CancerConsult (FR)
OutcomeResponding Well
Lindsay, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Lindsay's Patient Story

Patient Info: Lindsay Wagner, Female, 40s | Stage IV

Biomarkers: ALK-positive mutation / ALK rearrangement

Metastatic Site: brain; liver; bone; kidneys; lungs;…

As of September 2024, Lindsay was still on lorlatinib/Lorbrena with her lungs, liver, and kidneys described as stable, while isolated brain/bone areas were treated with radiation and monitored.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Pulmonary large cell neuroendocrine cancer treated with airway procedures and pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR negative, ALK negative, ROS1 negative, TP53 negative, PD-L1 <1%, TMB 28.3 mut/Mb

Metastatic Site: bilateral lungs

Pembrolizumab-based treatment produced a complete remission, but multiple intrapulmonary metastases recurred in October 2021 after an 18-month progression-free interval. Further local airway treatment was performed and pembrolizumab continued.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer with brainstem metastasis: complete remission on chemotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: pons, right parietal lobe, brain

Stage IV NSCLC with pontine and right parietal brain metastases achieved complete remission after 2 years of chemotherapy with an anti-VEGF drug; the pontine lesion remained stable, and severe SRS-related central neuropathic pain improved after methadone escalation.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer: immunotherapy plus particle therapy halts progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 90%; high tumor mutational burden; PIK3CA ; TP53 mutation; MET mutation

Metastatic Site: left proximal femur

Stage IV oligometastatic NSCLC had good CT response to carboplatin, pemetrexed, and pembrolizumab, then no disease progression 6 months after PULSAR radiotherapy plus pembrolizumab; grade 2 pneumonitis improved with prednisone.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Seven-year response journey in EGFR-mutated metastatic lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: pleura, brain

About 7 years after presentation with metastatic lung adenocarcinoma, he remained on targeted therapy. Gefitinib controlled the disease for 5 years; after brain progression, osimertinib followed by stereotactic radiation produced a complete intracranial response.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage 1 EGFR lung adenocarcinoma treated with radiotherapy

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: EGFR exon 19 deletion; other common drivers not detected.

Stage IB EGFR exon 19 deletion lung adenocarcinoma was treated with definitive radiotherapy because of fragile condition after spinal cord infarction; at 5 months, the lesion showed no significant change and there was no recurrence or radiation pneumonitis.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Lung squamous cell carcinoma spreading to bone and intestine

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 positive in almost all tumor cells

Metastatic Site: bone (left femur), intestine, abdomen

Despite chemotherapy, immunotherapy and radiation, the lung cancer progressed with intestinal and extensive abdominal metastases, cachexia and gastrointestinal bleeding. Palliative care was planned, but he chose discharge and received no further treatment.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage 3 lung cancer: complete response to chemo and immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Tumor markers were normal during mesorectal nodule workup; lung molecular biomarkers were not reported.

No radiologic NSCLC recurrence was detected during 16 months of follow-up after complete response to cisplatin/docetaxel chemoradiation plus 1 year of durvalumab; the suspicious mesorectal nodule proved to be a benign organized thrombus.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-mutated lung cancer with acquired resistance to osimertinib

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR L858R; acquired EGFR T790M; acquired EGFR L718Q

Metastatic Site: pleura, bone

After temporary disease control with sequential EGFR-targeted therapies, the right lung lesion enlarged again in June 2021; she was alive at the latest follow-up.

PubMed Central
OutcomeSetback / Progression
Leah, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (spine, pelvis); malignant right pleural…

As of July 2024, Leah remained on daily Tagrisso with stable Stage IV EGFR-mutated lung cancer, no reported progression, healing/sclerotic bone metastases, and durable response for more than 4 years.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Lung CancerLung Cancer

Second primary lung cancer treated with SBRT two years later

Patient Info: Anonymized, male, 70+

At 17 months after the second SBRT, the left-lung lesion had shrunk with no local recurrence, and the patient remained alive and walking independently.

PubMed Central
OutcomeResponding Well
Lenny, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Lenny's Survivor Story

Patient Info: Lenny, Male, 50s | Stage IV

Biomarkers: PD-L1 expression positive

Metastatic Site: right femur; brain/cerebellum

As of July 2024, Lenny described himself as NED/no evidence of disease after surgery, CyberKnife radiation, chemotherapy, and Keytruda-based immunotherapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Five-year survival with extensive-stage small cell lung cancer on atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: bilateral lungs, cervical lymph nodes

Five years after diagnosis with extensive-stage small cell lung cancer, he was alive and well on maintenance atezolizumab with no further documented progression after the 2020–2021 rechallenge, reaching 60 months overall survival and about 44 months progression-free survival.

PubMed Central
OutcomeResponding Well